Leap Therapeutics, Inc. (NASDAQ:LPTX) released significant updates regarding its recent clinical findings and corporate presentation. In a press release titled “Leap Therapeutics Reports Initial ...

Leap Therapeutics (NASDAQ:LPTX – Get Free Report) was downgraded by Baird R W from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports. Several other ...

The most recent announcement from Laowa is not a new lens but the release of the company’s new short film, The Leap Beneath, ...

When we came upon this area, I told my husband to stop. I took a few shots, and this was my favorite,' Wendy Hampe said.

Fintel reports that on January 29, 2025, HC Wainwright & Co. downgraded their outlook for Leap Therapeutics (NasdaqCM:LPTX) ...

Leap Therapeutics (LPTX) stock extends losses as Baird downgrades citing disappointing trial data the company posted for its lead asset sirexatamab. Read more here.

Last week, we looked at occurrences at Lover’s Leap from 1915 through 1938; this week we will cover from the forties to the ...

H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock ...

San Francisco and Bengaluru-based overseas education startup Leap has secured $65 Mn (INR 562.7 Cr) as a part of its Series E ...

Overseas education company Leap has raised USD $65 million in Series E funding, bringing its total equity backing to ...

Leap Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -70.45%. The profit margin, also known as the revenue ratio or gross profit ratio, ...

Leap Therapeutics is discontinuing the development of its anti-DKK1 antibody sirexatamab in gastric cancer after the drug ...